Switch theme
Sign up to access all valuation multiples
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
1949
95K+
LTM Revenue $34.1B
LTM EBITDA $9.8B
$139B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medtronic has a last 12-month revenue (LTM) of $34.1B and a last 12-month EBITDA of $9.8B.
In the most recent fiscal year, Medtronic achieved revenue of $33.5B and an EBITDA of $9.2B.
Medtronic expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medtronic valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $34.1B | XXX | $33.5B | XXX | XXX | XXX |
| Gross Profit | $22.3B | XXX | $21.9B | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $9.8B | XXX | $9.2B | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 27% | XXX | XXX | XXX |
| EBIT | $8.7B | XXX | $6.5B | XXX | XXX | XXX |
| EBIT Margin | 26% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $7.1B | XXX | $4.7B | XXX | XXX | XXX |
| Net Margin | 21% | XXX | 14% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $26.2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, Medtronic's stock price is $93.
Medtronic has current market cap of $119B, and EV of $139B.
See Medtronic trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $139B | $119B | XXX | XXX | XXX | XXX | $5.51 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, Medtronic has market cap of $119B and EV of $139B.
Medtronic's trades at 4.2x EV/Revenue multiple, and 15.6x EV/EBITDA.
Equity research analysts estimate Medtronic's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Medtronic has a P/E ratio of 16.8x.
See valuation multiples for Medtronic and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $119B | XXX | $119B | XXX | XXX | XXX |
| EV (current) | $139B | XXX | $139B | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | 4.2x | XXX | XXX | XXX |
| EV/EBITDA | 14.2x | XXX | 15.6x | XXX | XXX | XXX |
| EV/EBIT | 15.9x | XXX | 22.4x | XXX | XXX | XXX |
| EV/Gross Profit | 6.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 16.8x | XXX | 27.5x | XXX | XXX | XXX |
| EV/FCF | 24.7x | XXX | 26.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMedtronic's last 12 month revenue growth is 5%
Medtronic's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Medtronic's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Medtronic's rule of X is 42% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Medtronic and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | 9% | XXX | XXX | XXX |
| Rule of 40 | 32% | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 42% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medtronic acquired XXX companies to date.
Last acquisition by Medtronic was XXXXXXXX, XXXXX XXXXX XXXXXX . Medtronic acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Medtronic founded? | Medtronic was founded in 1949. |
| Where is Medtronic headquartered? | Medtronic is headquartered in United States of America. |
| How many employees does Medtronic have? | As of today, Medtronic has 95K+ employees. |
| Who is the CEO of Medtronic? | Medtronic's CEO is Ms. Que Thanh Dallara. |
| Is Medtronic publicy listed? | Yes, Medtronic is a public company listed on NYS. |
| What is the stock symbol of Medtronic? | Medtronic trades under MDT ticker. |
| When did Medtronic go public? | Medtronic went public in 1972. |
| Who are competitors of Medtronic? | Similar companies to Medtronic include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Medtronic? | Medtronic's current market cap is $119B |
| What is the current revenue of Medtronic? | Medtronic's last 12 months revenue is $34.1B. |
| What is the current revenue growth of Medtronic? | Medtronic revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Medtronic? | Current revenue multiple of Medtronic is 4.1x. |
| Is Medtronic profitable? | Yes, Medtronic is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Medtronic? | Medtronic's last 12 months EBITDA is $9.8B. |
| What is Medtronic's EBITDA margin? | Medtronic's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Medtronic? | Current EBITDA multiple of Medtronic is 14.2x. |
| What is the current FCF of Medtronic? | Medtronic's last 12 months FCF is $5.6B. |
| What is Medtronic's FCF margin? | Medtronic's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of Medtronic? | Current FCF multiple of Medtronic is 24.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
